An observational study in In-Stent Coronary Artery Restenosis and Coronary Artery Disease, sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To compare the angiographic and clinical outcomes of aggressive versus standard balloon preparation during drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR). The study will evaluate whether more aggressive lesion preparation with cutting/scoring/OPN balloons improves outcomes compared to standard preparation with semi-compliant or non-compliant balloons.
PICCOLETO XI A-PREP is an investigator-initiated, multicenter, international, observational study evaluating the impact of lesion preparation strategies on outcomes following drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR).
In-stent restenosis remains a clinically relevant challenge despite advances in drug-eluting stent technology and contemporary percutaneous coronary intervention techniques. DCB represents a stentless therapeutic strategy for ISR treatment, with the advantage of avoiding implantation of additional metallic layers.
A key determinant of clinical outcomes in ISR, particularly with DCB angioplasty, is the adequacy of lesion preparation before definitive therapy. Effective preparation facilitates optimal drug delivery, improves luminal gain, and may reduce the risk of recurrent restenosis.
A large spectrum of balloon-based modalities is available for ISR lesion preparation, ranging from semi-compliant and non-compliant balloons to more aggressive tools such as scoring and cutting balloons. Although more aggressive devices may enhance plaque modification and neointimal tissue disruption, their incremental clinical benefit over standard approaches remains uncertain.
Patients will be categorized into two groups based on lesion preparation strategy:
Clinical outcomes will be assessed at 1-year and longest available follow-up.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
This study's planned enrollment of 500 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Fondazione Ricerca e Innovazione Cardiovascolare ETS is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients who underwent drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR) at participating centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Lack of clinical outcome assessment
Patients who underwent lesion preparation using cutting/Wolverine balloons, scoring balloons (any brand), and/or OPN balloons prior to DCB angioplasty for ISR.
Patients who underwent lesion preparation using semi-compliant balloons and/or non-compliant balloons prior to DCB angioplasty for ISR.
Major Adverse Cardiovascular Events (MACE)
Composite of cardiac death, non-fatal myocardial infarction (MI), or target lesion revascularization (TLR).
Time frame: 12 months
Cardiac Death
Death attributed to cardiovascular causes, including death from unknown cause.
Time frame: 12 months and longest available follow-up
Non-fatal Myocardial Infarction
Non-fatal myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction.
Time frame: 12 months and longest available follow-up
Target Lesion Revascularization (TLR)
Any repeat revascularization (percutaneous or surgical) of the target lesion.
Time frame: 12 months and longest available follow-up
Target Vessel Myocardial Infarction (TV-MI)
Myocardial infarction attributable to the target vessel based on clinical, electrocardiographic, and biomarker criteria.
Time frame: 12 months and longest available follow-up
BARC Major Bleeding
Bleeding Academic Research Consortium (BARC) major bleeding events (type 3-5).
Time frame: 12 months and longest available follow-up
Procedural Success
Successful DCB angioplasty with residual stenosis less than 30% and TIMI flow grade 3 without major procedural complications.
Time frame: At procedure
Post-procedural Diameter Stenosis
Percentage of diameter stenosis after DCB angioplasty assessed by quantitative coronary angiography.
Time frame: At procedure
Angiographic Dissection
Presence and type of coronary dissection after lesion preparation and DCB treatment.
Time frame: At procedure
TIMI Flow Grade
Thrombolysis In Myocardial Infarction (TIMI) flow grade assessment post-procedure.
Time frame: At procedure
No study locations are listed for this record.
Plan to share: Undecided — Individual participant data may be made available to qualified researchers upon reasonable request after study completion and primary publication, subject to appropriate data use agreements and ethics committee approval.
Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Ricerca e Innovazione Cardiovascolare ETS